SCHEMBL1920154

SCHEMBL1920154

CCOC(=O)c1[nH]c2c(F)cncc2c1Nc1ccc([Si](C)(C)C)cc1F

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
MAP2K1 Q02750 3/20 0.36
KDM4E B2RXH2 6/20 0.36
HPGD P15428 5/20 0.36
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HSD17B10 Q99714 3/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36
THRB P10828 1/20 0.36
KMT2A Q03164 4/20 0.35
MAP2K2 P36507 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 2/20 0.34
MEN1 O00255 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1920037 0.92 TP53 (0.36) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL1922230 0.87 MAP2K1 (0.47) MAP2K1SMN1; SMN2LMNAMAP2K2
SCHEMBL1920337 0.86 MAPT (0.43) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL1215366 0.80 DHODH (0.38) MAPTMAP2K1KDM4EHPGDALDH1A1
SCHEMBL2565520 0.80 MAP2K1 (0.52) MAPTMAP2K1KDM4EALDH1A1LMNA
SCHEMBL1921544 0.79 MAP2K1 (0.45) MAP2K1SMN1; SMN2LMNAMAP2K2
SCHEMBL1920033 0.78 MAP2K1 (0.38) MAPTMAP2K1SMN1; SMN2THRBMAP2K2
SCHEMBL2567376 0.77 MAP2K1 (0.44) MAPTMAP2K1KDM4EHSD17B10THRB
SCHEMBL2565971 0.77 MAP2K1 (0.45) MAP2K1KDM4ELMNATHRBMAP2K2
SCHEMBL2569311 0.76 MAP2K1 (0.45) MAPTMAP2K1KDM4ELMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099796-B1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2011-06-01 EP disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE CDKN1A, MKI67, CCNI MAPT 4374/4885MAP2K1 24/4885KDM4E 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.